Activating mutations in the tyrosine kinase Janus kinase 2 (JAK2) cause myeloproliferative neoplasms, clonal blood stem cell disorders with a propensity for leukaemic transformation. Leukaemia inhibitory factor (LIF) signalling through the JAK-signal transducer and activator of transcription (STAT) pathway enables self-renewal of embryonic stem (ES) cells. Here we show that mouse ES cells carrying the human JAK2V617F mutation were able to self-renew in chemically defined conditions without cytokines or small-molecule inhibitors, independently of JAK signalling through the STAT3 or phosphatidylinositol-3-OH kinase pathways. Phosphorylation of histone H3 tyrosine 41 (H3Y41) by JAK2 was recently shown to interfere with binding of heterochromatin protein 1α (HP1α). Levels of chromatin-bound HP1α were lower in JAK2V617F ES cells but increased following inhibition of JAK2, coincident with a global reduction in histone H3Y41 phosphorylation. JAK2 inhibition reduced levels of the pluripotency regulator Nanog, with a reduction in H3Y41 phosphorylation and concomitant increase in HP1α levels at the Nanog promoter. Furthermore, Nanog was required for factor independence of JAK2V617F ES cells. Taken together, these results uncover a previously unrecognized role for direct signalling to chromatin by JAK2 as an important mediator of ES cell self-renewal.
The formation of mature blood cells from haematopoietic stem cells (HSCs) is the best characterized adult stem cell system. More than ten distinct mature lineages are generated from the multipotent HSCs through a plethora of oligopotent and unipotent progenitors, all of which can be identified by their cell-surface marker expression. Haematopoietic malignancies are caused by acquired mutations that perturb the balance between proliferation and differentiation of blood stem and/or progenitor cells. The myeloproliferative neoplasms (MPNs) are characterized by an overproduction of cells of one or more myeloid lineages and arise as a consequence of somatically acquired mutations in haematopoietic stem or progenitor cells 1, 2 . Activating mutations of the non-receptor tyrosine kinase Janus kinase 2 (JAK2) occur in the vast majority of patients with polycythaemia vera, an MPN characterized by overproduction of erythroid cells [3] [4] [5] [6] . The mutant JAK2V617F allele is the result of a point mutation within the JH2 pseudo-kinase domain of JAK2, which results in activation of downstream signalling pathways in the absence of relevant cytokines 3, 4 .
Murine embryonic stem (ES) cells are derived from the inner cell mass of the developing mouse blastocyst. They can be maintained in culture indefinitely, while retaining the ability to differentiate into all somatic cell types. ES cells are commonly isolated and maintained using a combination of the interleukin class 6 cytokine leukaemia inhibitory factor (LIF) and foetal calf serum (FCS) [7] [8] [9] . LIF signals through JAKs and involves activation of signal transducer and activator of transcription 3 (STAT3) 10 , which is essential for LIF-dependent ES cell self-renewal 11 . FCS can be replaced by the addition of bone morphogenetic protein (BMP4), thus enabling ES cell culture in chemically defined conditions 12 . More recently, it has been demonstrated that both LIF and BMP can be replaced by two small-molecule inhibitors of extracellular signal-regulated kinase (ERK) and glycogen synthase kinase 3 (GSK3) pathways; the presence of these inhibitors is known as 2i growth conditions 13 .
JAK signalling therefore controls the balance between self-renewal and differentiation of both HSCs and ES cells. To gain new insights into the underlying processes, we examined the molecular consequences of the JAK2V617F mutation in the context of ES cell self-renewal. ES cells engineered to contain the JAK2V617F mutant allele were able to self-renew in chemically defined conditions without any cytokines or small-molecule A R T I C L E S inhibitors. Moreover, cytokine-independent growth did not require STAT3 function but was sensitive to the level of the pluripotency regulator Nanog. We have recently shown that JAK2 can phosphorylate tyrosine 41 of histone H3 (H3Y41ph) and thus interfere with HP1α binding 14 . Here we show that inhibition of JAK2 signalling reduced Nanog expression, which was coupled to a decrease in H3Y41ph and concomitant increase in HP1α at the Nanog promoter. Our results are therefore consistent with a LIF-independent role for JAK proteins in ES cell self-renewal, whereby direct JAK signalling to chromatin contributes to the regulation of genes important for pluripotency. JAK2V617F 
RESuLTS

JAK2V617F enables factor-independent ES cell self-renewal
To gain new insights into the molecular consequences of the JAK2V617F mutation, a human JAK2 cDNA containing the V617F mutation was introduced by homologous recombination into the Jak2 locus of murine ES cells (Fig. 1a ). The mutant cDNA was under the normal regulatory control of endogenous Jak2 and the JAK2V617F allele was expressed at an equal level to the wild-type allele 15 . ES cells can be maintained in 2i growth conditions; JAK signalling in this context was thought to be unimportant because 2i obviates the requirement for STAT3 phosphorylation by JAK kinases 13 . However, when JAK2V617F ES cells were grown in 2i conditions at clonal density, there was a substantial increase in the number of ES cell colonies compared to the number seen with wild-type ES cells in these conditions. This observation led us to hypothesize that there may be a previously unknown requirement for JAK signalling in ES cells. A hallmark of MPNs is the ability to form erythroid colonies from patients' bone marrow without exogenous erythropoietin 16 . ES cells are usually supplemented with LIF to promote self-renewal. Because LIF and erythropoietin both signal through JAKs associated with their respective receptor 10,17 , we tested whether JAK2V617F ES cells could be maintained without the need for supplementary LIF. Unlike wild-type ES cells, JAK2V617F ES cells could grow for multiple passages either in serum-containing medium or in chemically defined media (N2B27) supplemented with BMP4, remaining in an undifferentiated state without the need for LIF supplementation ( Supplementary Information, Fig. S1) . Surprisingly, when BMP4 was also withdrawn from the culture medium, JAK2V617F ES cells remained in an undifferentiated state ( Fig. 1b ) and could be maintained in chemically defined media for over 50 passages without the addition of cytokines or small-molecule inhibitors. Factorindependent JAK2V617F ES cells retained a stable diploid karyotype and were morphologically indistinguishable from the parental ES cells ( Fig. 1b and Supplementary Information, Fig. S1 ). JAK2V617F ES cells converted to factor-independent growth after undergoing a crisis in which they detached from the gelatine substrate and formed spheres, but when replated in fresh N2B27, they reattached and continued to grow as a monolayer (Fig. 1b ). This conversion was required for clonal expansion of factor-independent JAK2V617F ES cells ( Fig. 1c ). Factorindependent JAK2V617F ES cells formed ES cell colonies with similar efficiency to wild-type ES cells in serum and LIF or in LIF and BMP4, but were more efficient in 2i ( Fig. 1c ). Factor-independent growth was abolished when ES cells were grown in N2B27 in the presence of a smallmolecule inhibitor of JAK (AG490) 18 (Fig. 1c ).
To confirm that acquisition of cytokine independence was not an isolated event, 48 JAK2V617F-positive clones were picked, 45 of which were successfully expanded and all 45 clones could be maintained in N2B27 alone for at least five passages ( Supplementary Information, Fig. S1 ). Factor-independent JAK2V617F ES cells expressed the ES cell markers OCT4 and Nanog, similarly to parental ES cells grown in N2B27 plus LIF and BMP4 ( Fig. 1d ). Genome-wide expression profiling was performed using parental ES cells, JAK2V617F ES cells maintained in N2B27 plus LIF and BMP4 and JAK2V617F ES cells grown in N2B27. The majority of genes were expressed at similar levels in all three samples, and there was a strong correlation coefficient for all two-way comparisons (Fig. 1e ). Known regulators of ES cell identity were expressed at similar levels (for example, OCT4 and SOX2) or slightly elevated levels (for example, Nanog) in JAK2V617F ES cells, and there was no upregulation of genes characteristic of more committed cell types ( Fig. 1f ). Expression profiling therefore confirmed that the transcriptome of factor-independent JAK2V617F ES cells was highly similar to that of parental wild-type ES cells.
Factor-independent JAK2V617F ES cells were not permanently locked into an undifferentiated state; they could differentiate in vitro into somatic cell types, including erythrocytes and neurons ( Fig. 2a ), but in vitro differentiation was less efficient. Haematopoietic differentiation of factor-independent JAK2V617F ES cells resulted in fewer cells positive for the mesoderm marker fetal liver kinase 1 (FLK-1) than did differentiation of wild-type ES cells at 3, 5 and 7 days after the Figure 2 Factor-independent JAK2V617 ES cells are capable of multilineage differentiation in vitro and in vivo. (a) Factor-independent JAK2V617F ES cells give rise to embryoid bodies containing red blood cells and differentiate into neurons when transferred into appropriate differentiation conditions. (b) JAK2V617F ES cells generate FLK-1-positive mesodermal cells with delayed differentiation kinetics. Wild-type and factorindependent JAK2V617F ES cells were differentiated to haematopoietic lineages, and the proportion of FLK-1 and SSEA-1-positive cells were measured by fluorescence-activated cell sorting (FACS) at days 3, 5 and 7 of differentiation. (c) Teratocarcinoma formation from JAK2V617F ES cells. Parental AB2.2 ES cells maintained in N2B27 plus LIF and BMP4 and factor-independent JAK2V617F ES cells were injected into the kidney capsule of 129sv mice and left for 4 weeks. These examples show that teratocarcinomas consisting of cells from all three germ layers formed, but the majority of teratocarcinomas from factor-independent JAK2V617F ES cells remained undifferentiated or were of no immediately discernible cell type. Un, undifferentiated; ec, ectoderm; me, mesoderm; en, endoderm.
nature cell biology VOLUME 13 | NUMBER 1 | JANUARY 2011 start of differentiation, with cells expressing the ES cell marker SSEA-1 still persisting at day 7 ( Fig. 2b ). To evaluate in vivo multi-lineage differentiation of factor-independent JAK2V617F ES cells, injections into mouse kidney capsule were performed, which resulted in formation of teratocarcinomas composed of all three germ layers ( Fig. 2c ). Unlike parental teratocarcinomas, however, teratocarcinomas from factorindependent JAK2V617F ES cells were composed predominantly of undifferentiated or poorly differentiated cells ( Fig. 2c ), indicating that although differentiation was possible, it was dramatically reduced by the presence of JAK2V617F. Factor-independent JAK2V617F ES cells were also injected into 8-cell-stage mouse embryos and transplanted into recipient females; no chimaeras were observed either embryonically or postnatally following three independent rounds of injections ( Supplementary Information, Fig. S1 ). Correct timing of differentiation is essential for integration of ES cells into the developing blastocyst. Delayed or inefficient differentiation is likely to have excluded factorindependent ES cells from contributing to chimaeras, thus making them fail one of the classical criteria of pluripotency.
Our demonstration that mutant JAK2 influenced ES cell self-renewal raised the possibility that this pathway may be required in wild-type ES cells. We therefore investigated the clonogenicity of wild-type and JAK2V617F ES cells in the presence of pan-JAK (AG490 18 and Jaki1 19 ) and JAK2-selective (TG101209 20 ) inhibitors when grown in 2i conditions, which obviate the requirement for STAT3 activity 13 . There was a dose-dependent decrease in the number of ES cell clones formed in the presence of all inhibitors. Moreover, JAK2V617F ES cells grown in 2i or N2B27 show a similar sensitivity to JAK inhibitors ( Fig. 3a , Supplementary Information, Table S1 ) and these effects were seen at concentrations considerably lower than routinely used 14, [18] [19] [20] . Time-lapse microscopy of parental or JAK2V617F ES cells showed that ES cells cannot be maintained in a self-renewing state in 2i media following the addition of AG490. Instead, they lost characteristic ES cell morphology and began to form cells that appear more differentiated (Supplementary Information, movies). Together with the in vitro differentiation and teratocarcinoma assays, these results demonstrate that factor-independent JAK2V617F ES cells are not transformed into a permanently self-renewing ES cell state.
Factor-independent ES cell self-renewal is independent of the JAK/STAT pathway To understand the molecular basis of factor-independent self-renewal and the role of JAK2 in LIF-independent ES cell self-renewal, the Table S1 . Uncropped images of blots are shown in Supplementary Information, Fig. S7 .
pathways regulated by JAK2 were analysed. Extracellular binding of cytokines induces receptor-bound JAKs to recruit and phosphorylate STAT proteins, which then dimerize and translocate to the nucleus, where they regulate transcription 21 . STAT3 is the only STAT family member expressed in wild-type or JAK2V617F ES cells ( Supplementary  Information, Fig. S2 ), and STAT3 is essential in LIF-dependent ES self-renewal 11, 13 . LIF induces STAT3 phosphorylation 10, 22 , and constitutively active STAT3 removes the need for LIF to promote self-renewal 23 . JAK2V617F ES cells, in either N2B27 alone or 2i medium, do not contain detectable STAT3 phosphorylation (Fig. 3b ).
Because of the importance of the JAK-STAT axis in ES cell selfrenewal 10, 11, 22, 23 and in MPNs 24, 25 , JAK regulation of STAT3 was investigated further. Firstly, the expression profile for various known transcriptional targets of STAT3 signalling were compared; genes including Suppressor of cytokine signalling 3 (SOCS3) were significantly downregulated in factor-independent JAK2V617F ES cells compared to wild-type or JAK2V617F ES cells growing in LIF ( Supplementary  Information, Fig. S2 ). Secondly, STAT3-null ES cells grown in 2i conditions were treated with the same panel of JAK inhibitors described previously and their clonogenicity was tested. STAT3-null ES cells showed a similar sensitivity to that of wild-type ES cells when treated with JAK inhibitors, suggesting that the diminished self-renewal caused by inhibiting JAK signalling in 2i conditions occurs independently from STAT3 ( Fig. 3c and Supplementary Information, Table S1 ). Finally, the JAK2V617F construct was introduced by homologous recombination into STAT3-null ES cells ( Supplementary Information, Fig. S3 ), and JAK2V617F STAT3-null ES cells were tested for their ability to be maintained in factor-independent conditions. Eleven JAK2V617F STAT3-null ES cell clones were successfully grown for five passages or more in N2B27 alone ( Supplementary Information, Fig. S3 ), and they continued to express the key ES cell markers OCT4 and Nanog (Fig. 3d ). Taken together, these experiments demonstrate that factorindependent self-renewal is not conferred by LIF-independent activation of STAT3.
Phosphoinositide-3-OH kinase (PI(3)K) is a downstream target of JAK signalling and promotes ES cell self-renewal by a pathway that entails phosphorylation of protein kinase B (also called AKT) 22, 26 . However, the level of phosphorylated AKT in JAK2V617F ES cells was unaffected by the addition of the JAK inhibitor AG490 (Fig. 3b) and was elevated only following the addition of LIF (Fig. 3b) . Moreover, gene set enrichment analysis of the microarray data shows that there was no significant change in PI(3)K pathways in factor-independent JAK2V17F ES cells grown in N2B27 compared to wild-type ES cells grown in LIF and BMP4 ( Supplementary Information, Fig. S4 ). JAK2V617F regulation of PI(3)K therefore was unlikely to be important for factor-independent self-renewal. Activation of ERK1/2 and the small GTPase Ras, two other downstream targets of JAK signalling, promotes ES cell differentiation [27] [28] [29] [30] . However, ERK1/2 was still phosphorylated in factorindependent JAK2V617F ES cells ( Supplementary Information, Fig. S4 ), and JAK2V617F ES cell self-renewal was enhanced by inhibiting ERK signalling ( Fig. 1c ), suggesting that factor-independent self-renewal is not conferred by loss of ERK activation.
JAK2 signals directly to chromatin in ES cells by phosphorylating histone H3Y41
Studies in Drosophila have shown that JAK signalling globally counteracts heterochromatic gene silencing by antagonizing the function of heterochromatin protein 1 (HP1) 31, 32 . Moreover, we have recently identified a novel role for JAK2 in the nucleus of haematopoietic cells, where it can phosphorylate tyrosine 41 of histone H3 (H3Y41); this phosphorylation interferes with HP1α binding 14 and thus provides a molecular explanation for the JAK2 activity uncovered from Drosophila genetics. Phosphorylated JAK2 was present in the nucleus of ES cells ( Fig. 4a ) and we therefore investigated whether JAK2V617F alters the distribution of HP1α. Chromatin-bound HP1α, but not OCT4, was lower in JAK2 mutant compared to wild-type ES cells, under multiple growth conditions (Fig. 4b ).
To confirm that HP1α is dynamically regulated by JAK2, JAK inhibitor TG101209 was added to JAK2V617F ES cells grown in factor-independent conditions. Following 2 h of treatment there was a significant increase of chromatin-associated HP1α in the nucleus (Fig. 4c ) and a decrease in the global level of H3Y41ph ( Fig. 4d , Supplementary  Information, Fig. S5 ). The decrease in H3Y41ph levels was observed as early as 15 min after JAK inhibitor treatment ( Supplementary  Information, Fig. S5 ), which is not only consistent with the direct link between JAK2 and H3Y41 phosphorylation but also highlights the very dynamic nature of the H3Y41ph histone modification. Importantly, these results indicate that inhibition of JAK2 in ES cells is accompanied by an increase in chromatin-bound HP1α.
Nanog is a critical target for LIF-independent JAK signalling
The pluripotency transcription factor Nanog is expressed at elevated levels in JAK2V617F ES cells compared to wild-type cells in both cytokine-containing and cytokine-independent conditions (Fig. 1f ). Nanog was also downregulated at the protein level following a 2 h treatment with TG101209 ( Fig. 4c, d) . On the basis of the data presented above, these observations are consistent with a model whereby JAK2 may regulate Nanog expression by controlling the level of phosphorylated H3Y41 at the Nanog promoter. We therefore carried out chromatin immunoprecipitation (ChIP) for phosphorylated H3Y41 in factor-independent JAK2V617F ES cells grown in N2B27 and in N2B27 plus the JAK inhibitor TG101209 for 6 h. We mapped a 8 kb window spanning the Nanog transcriptional start site; phosphorylated H3Y41 was present surrounding the transcriptional start site of Nanog, but was reduced following treatment with TG101209 ( Fig. 5a ). These changes were coupled with an increase in the binding of HP1α and decrease in methylation of histone H3 lysine 4 (H3K4me) at the Nanog promoter ( Supplementary Information, Fig. S5 ). These reciprocal changes in H3Y41ph and HP1α binding following JAK inhibition were also seen in wild-type ES cells growing in LIF-independent conditions (Fig. 5b ), suggesting that loss of H3Y41ph and HP1α recruitment are involved in regulating Nanog expression.
To further characterize this newly discovered link between JAK2 and Nanog, Nanog overexpressing ES cells 33 were analysed in the ES cell clonogenicity assay with the panel of JAK inhibitors described above. Although JAK inhibition caused a reduction in the self-renewal ability of Nanog overexpressing ES cells, this was significantly less than the decline observed with wild-type ES cells (Fig. 5c ), indicating that Nanog overexpression can largely overcome the effect of JAK inhibition. Conversely, factor-independent ES cell self-renewal of JAK2V617F ES cells transduced with short hairpin RNA (shRNA) vector targeting Nanog 34 was severely compromised when compared with control vector transduced cells (Fig. 5d ), indicating that Nanog is required for factor-independent self-renewal of JAK2V617F ES cells. Although the above results demonstrate a central role for Nanog in JAK2V617F-mediated factor-independent self-renewal, our immunohistochemical analysis showed JAK-dependent H3Y41ph throughout the nucleus (Fig. 4d) . Therefore, various regulators of ES cell self-renewal were analysed to determine whether there was JAKdependent dynamic localization of H3Y41ph at their promoters. Some genes, such as SOX2 and SMARCA4 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A4), were dynamically regulated in a similar manner to Nanog, with JAK inhibition causing a reduction H3Y41ph and an increase in HP1α. Other genes, such as Bicaudal D homolog 2 (BICD2), DNA methyltransferase 1 (DNMT1) and T-box transcription factor 3 (TBX3), showed reduced H3Y41ph but no increase in HP1α, whereas DNMT3b had no H3Y41ph ( Supplementary  Information, Fig. S5 ). Multiple genes involved in ES cell self-renewal therefore show JAK-dependent dynamic regulation of H3Y1ph and HP1α, but detailed modes of regulation are likely to be gene-specific. Recruitment of HP1α by sequence-specific transcription factors has been observed previously 35, 36 , suggesting that loss of H3Y41ph alone is not sufficient for HP1α binding.
Multiple JAKs can phosphorylate H3Y41 Knockouts of single JAK family genes can survive beyond the epiblast stage of development [37] [38] [39] , which in light of our JAK inhibitor data suggests functional redundancy. We therefore wanted to ascertain whether this regulatory role for JAK2 signalling in ES cell self-renewal can also be conferred by other JAK family members. We derived JAK2-null ES cells ( Supplementary Information, Fig. S3 ) to identify whether H3Y41 was phosphorylated independently from JAK2. H3Y41ph was present in JAK2-null ES cells and was dynamically regulated by inhibiting JAK signalling. Moreover, there was a significant reduction in the global level of H3Y41ph following treatment with AG490, which was accompanied by differentiation of these inhibitor-treated JAK2-null ES cells, as seen by loss of OCT4 expression ( Fig. 6a ).
JAK1 has long been implicated in ES cell self-renewal 40 . We found that JAK1 was also present in the nucleus of wild-type ES cells grown in 2i ( Fig. 6b ) and that JAK1 can directly phosphorylate H3Y41 ( Supplementary Information, Fig. S6 ). Moreover, ES cells express all JAK family members ( Supplementary Information, Fig. S2 ), and JAKs other than JAK1 and JAK2 may also be involved in phosphorylating H3Y41. Our observation that H3Y41 can be phosphorylated by JAKs other than JAK2 coupled with our analysis of JAK2-null ES-cells suggests that although this pathway was discovered using JAK2, it probably involves multiple members of the JAK family.
DISCuSSION
Chromatin-modifying enzymes restrict ES cell differentiation to specific lineages 41, 42 , and chromatin modifications are dynamically redistributed during in vitro differentiation of ES cells 43, 44 . Here we not only demonstrate JAK2-mediated control of histone H3Y41 phosphorylation on the Nanog promoter, but also show global effects on heterochromatin. We therefore hypothesize that increased H3Y41 phosphorylation on key gene loci stabilizes the overall transcriptional regulatory state of ES cells. This model is not only consistent with our demonstration of cytokine-independent self-renewal, but would also explain the inability of factor-independent JAK2V617F ES cells to contribute to chimaeras and their comparatively low propensity to differentiate in teratocarcinoma assays.
Given the original identification of the JAK2V617F mutation in an adult stem cell disease, our results raise the intriguing possibility that at least part of the disease phenotype may arise from changes in the plasticity of chromatin. The JAK2V617F mutation occurs in blood stem cells, and mutant blood stem cells are thought to be biased towards producing myeloid progeny because the mutant allele is rarely detected in lymphocytes. Gene expression studies and evolutionary comparisons support the notion that myeloid differentiation is the default pathway for blood stem cells. It is therefore possible that the myeloid differentiation bias of JAK2V617F blood stem cells is mechanistically related to the cell fate stabilization phenotype uncovered here in JAK2V617F ES cells. Furthermore, many cancers are characterized by an increase in the level of activated JAK signalling 45 , which is often achieved by amplification of the amount of cytokine 46 or an increase in sensitivity of the receptor to cytokines 47 . Consequently, the level and distribution of H3Y41ph is likely to be altered, suggesting that JAK signalling to chromatin may have a wider role in human cancer and that changes in H3Y41ph should therefore also be examined in these diseases.
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Generation of JAK2V617F ES cells.
A cassette containing a floxed PGKNeoPoly(A) minigene followed by a mutant human JAK2V617F cDNA and a SV40 Poly(A) sequence was introduced into AB2.2 ES cells into the ATG translation start site in exon 2 using recombineering 50 . Targeted ES clones with the JAK2 F/+ allele were identified by Southern blot analysis 15 . Correctly targeted ES cells were subjected to electroporation of PGKCre. Single colonies were picked and analysed by PCR 15 .
Colony forming assays. ES cells were trypsinized to obtain a single cell suspension and 500 cells plated per 10 cm 2 well in triplicate. After 3 days the medium was changed, and after 6 days the cells were stained for alkaline phosphatase (Sigma) and colonies counted.
Gene expression analysis.
Total RNA was collected in triplicate from wild-type ES cells grown in N2B27 plus LIF and BMP4, JAK2V617F ES cells grown in N2B27 plus LIF and BMP4 and JAK2V617F ES cells in N2B27 alone using Tri reagent (Sigma). cDNA was synthesized and hybridized to Illumina Mouse WG-6 v1.0 Expression BeadChips. BeadChip probe-sets that did not pass the Illumina signal detection statistic at a threshold of p < 0.01 in all sample replicates of at least one sample group were removed from further analysis, leaving 18,697 expression values per profile. For all samples, the remaining probe-sets were background corrected and quantile normalized using the lumi package of the Bioconductor suite of software for R. Following comparison of sample group profiles, intergroup profile correlations were calculated using average linkage and the Spearman correlation measure, accompanied by standard error. Gene categories enriched following inter-group comparison were identified using the Gene Set Enrichment Analysis software 51 with default settings.
In vitro differentiation. Neural differentiation was performed as described previously 52 except that 10 µg/ml FGF4 (Peprotech) was supplemented into medium. Haematopoietic differentiation was performed by seeding ES cells in suspension in IMDM (Invitrogen) plus 15% FBS (Hyclone), 10% PFHM (Invitrogen), 1% l-glutamine (PAA Laboratories), 1% human transferrin (Roche), 0.3 mM MTG (Sigma) and 50 ng/ml AA (Sigma).
Teratocarcinoma and chimaera contribution assays. For teratocarcinoma induction, 1 × 10 6 cells of each ES cell line were injected subcutaneously into the kidney capsules of isoflurane-anaesthetized 129SV mice. Teratocarcinomas were recovered 3-4 weeks after injection, fixed overnight in formalin, paraffin embedded and sectioned. Sections were stained with haematoxylin and eosin and imaged using an Improvision Openlab deconvolution camera. For chimaeras, factor-independent JAK2V617F ES cells were injected into the 8-cell stage embryos of agouti 129SV/BL6 mice. For two rounds of injections, mice were born and examined for chimaeric coat colour; for the third round JAK2V617F ES cells had enhanced green fluorescent protein (eGFP) inserted into the ROSA26 locus and embryos were examined for eGFP-positive cells at E12.5.
JAK2-null ES cell derivation.
Heterozygous non-recombined JAK2V617F mice were crossed and blastocysts harvested at E3.5. ES cell derivation was performed as described in ref. 53 .
Immunohistochemistry, microscopy and flow cytometry. Images were captured with a Zeiss LSM510 meta confocal microscope. Image processing was performed with Photoshop (Adobe Systems). For fluorescent intensity analysis all images were captured using the same settings and unprocessed images were measured using ImageJ (NIH). Live cell imaging was performed using the IncuCyte platform (Essen instruments). Flow cytometry was performed on FACScalibur (BD). JAK inhibitors. AG490 (Millipore), Jaki1 (Calbiochem) and TG101209 (TargeGen Inc) were all used at 1 µM unless indicated otherwise.
Antibodies. Antibodies against the following proteins or epitopes with the indicated catalogue numbers were used at the indicated dilutions: OCT4 (Santa Cruz sc-5279) 1:125; Nanog (R&D systems AF2729) 1:250; Tuj1 (Abcam AB14545) Chromatin immunoprecipitation and RT-PCR. ES cells were treated for 16 h with either AG490 or dimethyl sulphoxide (DMSO). Chromatin was prepared and chromatin immunoprecipitation was performed as described previously 35 , with the following exceptions. Cells were crosslinked with 1% (v/v) formaldehyde for 15 min at room temperature and DNA was purified with the QIAquick PCR purification kit (Qiagen). Immunoprecipitated DNA was analysed on a Stratagene Mx3005P real-time PCR machine, with SYBRgreen PCR mastermix. The experiment was performed on two separate occasions using independent biological material. Primer sequences are available on request.
Kinase assay. Active JAK1 protein (Invitrogen) was used in an in vitro kinase assay. In brief, assays were performed in 50 μl HTScan kinase buffer (60 mM HEPES pH 7.9, 5 mM MgCl 2 , 5 mM MnCl 2 , 3 μM Na 3 VO 4 , 2.5 mM DTT, 100 μM ATP). Recombinant histones were used as substrates, and then probed with anti-H3Y41ph antibody (1:1000) overnight at 4 °C, followed by anti-rabbit secondary conjugated to horseradish peroxidase and developed using enhanced chemiluminescence. following Cre treatment and screened for recombination of the floxed allele. ES cells that were successfully recovered were expanded and passaged in N2B27 only the indicated number of times. 8 cell stage injections, no pups or embryos were found to contain any cytokine independent JAK2V617F ES cells. 
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